ReGen Biologics, Inc. Reports Successful Q1 Training Results

Published: Apr 09, 2009

HACKENSACK, N.J.--(BUSINESS WIRE)--ReGen Biologics (OTC: RGBO) (“ReGen” or “the Company”) announced today that it has trained 45 sports medicine surgeons in the use of its Menaflex™ collagen meniscus implant and over 30 sales representatives during the first three months of 2009. ReGen initiated U.S. training efforts in January 2009 after receiving FDA clearance of the Menaflex for the medial meniscus on December 18, 2008.

Back to news